Describing work towards an innovative and disruptive tuberculosis diagnostic technology exploiting unique aspects of the disease and disease progression that will be applicable at the point-of-care in several contexts.
Position in Company
Candidate researcher
Media
csir_news_default.webp
Topic
Can lateral flow immunoassays detect low affinity biomarker anti-lipid antibodies in tuberculosis?